Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 9,945 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Single-arm Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue

NCT00855088
View directory record Official record
Conditions
HIV/AIDS, HIV Infections
Interventions
darunavir, Ritonavir, Etravirine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2011 · Synced Nov 7, 2026, 1:46 AM EST
Completed Phase 1 Interventional

Pilot Study of Safety and Toxicity of Acquiring Hyperpolarized Carbon-13 Imaging in Children With Brain Tumors

NCT02947373
View directory record Official record
Conditions
Pediatric Brain Tumors
Interventions
Hyperpolarized Pyruvate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
3 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Nov 7, 2026, 1:46 AM EST
Recruiting Phase 1 Interventional

Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia

NCT07476183
View directory record Official record
Conditions
RPS19 Deficient Diamond-Blackfan Anemia
Interventions
APR-2020
Biological
Lead sponsor
Apriligen, Inc.
Industry
Eligibility
2 Years to 25 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Stanford, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 7, 2026, 1:46 AM EST
Not listed Phase 1Phase 2 Interventional

Robotic Brace Incorporating Electromyography (EMG) for Moderate Affected Arm Impairment After Stroke

NCT01322997
View directory record Official record
Conditions
Stroke
Interventions
Myomo e100 Robot and repetitive task specific training, Repetitive task specific training (RTP) targeting the affected arm, Myomo e100 neurorobotic brace
Device · Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
35 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 25, 2011 · Synced Nov 7, 2026, 1:46 AM EST
Active, not recruiting Phase 2 Interventional

The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer

NCT04699123
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer
Interventions
NC318 800 mg, NC318 400 mg, Pembrolizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Nov 7, 2026, 1:46 AM EST
Recruiting Phase 2 Interventional

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

NCT06295159
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, Melanoma
Interventions
Nivolumab, Nivolumab + Relatlimab, Ipilimumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 7, 2026, 1:46 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Research and Innovation to Stop E-cigarette/Vaping in Young Adults

NCT04974580
View directory record Official record
Conditions
Nicotine Dependence, E-Cig Use
Interventions
Nicotine patch, Phone Counseling, Digital Coaching
Drug · Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 24 Years
Enrollment
508 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Nov 7, 2026, 1:46 AM EST
Completed Phase 2 Interventional Results available

Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma

NCT03568461
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
tisagenlecleucel
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
9
States / cities
Duarte, California • San Francisco, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Nov 7, 2026, 1:46 AM EST
Completed Phase 3 Interventional Results available

Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection

NCT01596283
View directory record Official record
Conditions
Liver Cancer
Interventions
Standard fluid management, Goal directed fluid therapy with the Edwards EV1000 system
Procedure · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Nov 7, 2026, 1:46 AM EST
Recruiting Phase 2 Interventional

Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity

NCT07228741
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Obesity
Interventions
Tirzepatide, Resistance Exercise, Lifestyle Counseling
Drug · Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Nov 7, 2026, 1:46 AM EST
Suspended Phase 2 Interventional

Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

NCT05445609
View directory record Official record
Conditions
Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
Interventions
VLP-encapsulated TLR9 Agonist CMP-001,, Nivolumab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 7, 2026, 1:46 AM EST
Completed Phase 1 Interventional

Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines

NCT02408432
View directory record Official record
Conditions
Cardiomyopathy, Heart Failure
Interventions
Laboratory Biomarker Analysis, Standard of Care, Mesenchymal Stem Cell Transplantation
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Nov 7, 2026, 1:46 AM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

NCT02316106
View directory record Official record
Conditions
Multiple Myeloma
Interventions
daratumumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
15
States / cities
Little Rock, Arkansas • Jacksonville, Florida • West Palm Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Nov 7, 2026, 1:46 AM EST
Completed Phase 4 Interventional Results available

Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome

NCT02252406
View directory record Official record
Conditions
Stable Angina, Metabolic Syndrome
Interventions
Ranolazine, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
30 Years to 75 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 10, 2020 · Synced Nov 7, 2026, 1:46 AM EST
Active, not recruiting Phase 2 Interventional Results available

RElugolix VErsus LeUprolide Cardiac Trial

NCT05320406
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions
Radiation therapy, Leuprolide, Relugolix
Radiation · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Nov 7, 2026, 1:46 AM EST
Completed Not applicable Interventional

Program for Pain & Prescription Opioid Use in Pregnancy

NCT02804152
View directory record Official record
Conditions
Pain, Opioid Abuse, Pregnancy
Interventions
CBT for Chronic Pain in Pregnancy
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Nov 7, 2026, 1:46 AM EST
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease

NCT03976349
View directory record Official record
Conditions
Parkinson's Disease
Interventions
BIIB094, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
35 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Chicago, Illinois • Farmington Hills, Michigan • Cleveland, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Nov 7, 2026, 1:46 AM EST
Terminated Phase 4 Interventional Results available

Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit

NCT02025855
View directory record Official record
Conditions
Opioid Use, Unspecified With Withdrawal, Opioid-Induced Disorders, Delirium
Interventions
Methadone, Placebo
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Nov 7, 2026, 1:46 AM EST
Completed Phase 4 Interventional

Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

NCT04377555
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing
Interventions
Ocrelizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
26
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Nov 7, 2026, 1:46 AM EST
Completed Phase 2Phase 3 Interventional

Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior

NCT05767385
View directory record Official record
Conditions
Congenital Heart Disease in Children, Hypoxia, Neurodevelopmental Disorders, Complex Congenital Heart Disease
Interventions
Single Arm, Neonatal Neurobehavioral Scale
Procedure
Lead sponsor
University of Utah
Other
Eligibility
0 Years to 52 Years · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
San Francisco, California • Washington D.C., District of Columbia • Scarborough, Maine + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 7, 2026, 1:46 AM EST
Completed Phase 2 Interventional Results available

A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody

NCT03525678
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin frozen liquid, Belantamab mafodotin lyophilized powder
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
21
States / cities
New Haven, Connecticut • Atlanta, Georgia • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Nov 7, 2026, 1:46 AM EST
Completed Phase 4 Interventional Results available

Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD

NCT02228408
View directory record Official record
Conditions
Chronic Hemodialysis (ESRD)
Interventions
Hydralazine/Isorsorbide Dinitrate, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Nov 7, 2026, 1:46 AM EST
Completed Not applicable Interventional Results available

Feasibility of an Analgesic Device Enabling Local Anesthetic Delivery and Neuromodulation After Shoulder/Foot Surgery

NCT06818708
View directory record Official record
Conditions
Rotator Cuff Injuries, Shoulder Disease, Hallux Valgus, Ankle Arthropathy
Interventions
Experimental Treatment
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Nov 7, 2026, 1:46 AM EST
Completed Phase 4 Interventional

Mynx M5 One Hour Ambulation Study

NCT01100476
View directory record Official record
Conditions
Angiography
Interventions
Endovascular Diagnostic Procedures
Device
Lead sponsor
Cardiovascular Associates of the Delaware Valley
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Nov 7, 2026, 1:46 AM EST